Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.

Chen L, Adar R, Yang X, Monsonego EO, Li C, Hauschka PV, Yayon A, Deng CX.

J Clin Invest. 1999 Dec;104(11):1517-25.

2.
3.
4.
5.

Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.

Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM.

Nat Genet. 1996 Apr;12(4):390-7.

PMID:
8630492
6.

Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.

Su N, Sun Q, Li C, Lu X, Qi H, Chen S, Yang J, Du X, Zhao L, He Q, Jin M, Shen Y, Chen D, Chen L.

Hum Mol Genet. 2010 Apr 1;19(7):1199-210. doi: 10.1093/hmg/ddp590. Epub 2010 Jan 6.

7.
8.
9.

FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: implications for endochondral ossification.

Weizmann S, Tong A, Reich A, Genina O, Yayon A, Monsonego-Ornan E.

Matrix Biol. 2005 Dec;24(8):520-9. Epub 2005 Oct 25.

PMID:
16253490
10.
12.

Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.

Pannier S, Mugniery E, Jonquoy A, Benoist-Lasselin C, Odent T, Jais JP, Munnich A, Legeai-Mallet L.

Bone. 2010 Nov;47(5):905-15. doi: 10.1016/j.bone.2010.07.020. Epub 2010 Jul 29.

PMID:
20673820
14.

Mouse models orthologous to FGFR3-related skeletal dysplasias.

Brodie SG, Deng CX.

Pediatr Pathol Mol Med. 2003 Jan-Feb;22(1):87-103. Review.

PMID:
12687892
15.

FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.

Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D, Murakami S.

Hum Mol Genet. 2009 Jan 15;18(2):227-40. doi: 10.1093/hmg/ddn339. Epub 2008 Oct 15.

16.

A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.

Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, Gorivodsky M, Pines M, Yayon A, Lonai P, Givol D.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4455-60.

17.

[From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].

van Ravenswaaij-Arts CM, Losekoot M.

Ned Tijdschr Geneeskd. 2001 Jun 2;145(22):1056-9. Review. Dutch.

PMID:
11414167
18.

[Gly374Arg mutation in Fgfr3 causes achondroplasia in mice].

Wang JM, Du XL, Li CL, Yin LJ, Chen B, Sun J, Su N, Zhao L, Song RH, Song WW, Chen L, Deng CX.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Dec;21(6):537-41. Chinese.

PMID:
15583977
19.

Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.

Aviezer D, Golembo M, Yayon A.

Curr Drug Targets. 2003 Jul;4(5):353-65. Review.

PMID:
12816345
20.

Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes.

Zhou ZQ, Ota S, Deng C, Akiyama H, Hurlin PJ.

Hum Mol Genet. 2015 Mar 15;24(6):1764-73. doi: 10.1093/hmg/ddu594. Epub 2014 Nov 28.

Supplemental Content

Support Center